Alisa Selimovic
It’s a really exciting time to be a science-focused VC in Australia, particularly in the life sciences. The convergence of world-class medical research with a thriving, expanding public and private funding ecosystem means that innovation in this space is accelerating at a rate that has us sprinting to keep up.
Alisa has always been interested in translational science, but did not always know that working as a VC would be her dream job. In her current role as Senior Investment Manager in the Life Sciences, Alisa has the privilege of working with exceptional scientists every day - both within the IP Group team, and within Australia’s university research ecosystem - to build new companies working at the cutting edge of medical research.
Alisa joins IP Group Australia from the University of Sydney where she was the Business Development Manager for the Faculty of Medicine, responsible for developing new industry-academia partnerships with both local and global industry players. Prior to her return to Australia in 2017, Alisa spent eight years in Oxford, UK, where she worked in life sciences strategy and M&A consulting at PharmaVentures, and in the Corporate Development team at Circassia, where she worked on the company’s £275M acquisition of Prosonix and Aerocrine. Alisa holds a DPhil in Biomedical Engineering from Oxford, and a Bachelor of Engineering / Bachelor of Life Sciences from Flinders University.